Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on AQST stock, giving a Buy rating on April 2.
Roanna Ruiz’s rating is based on Aquestive Therapeutics’ strategic progress and promising developments with their oral epinephrine film, Anaphylm. The company has successfully shared detailed results from their pediatric trial for patients aged 7-17 years, which has been a point of interest for investors. Additionally, the completion of their NDA filing for Anaphylm marks a significant milestone, with expectations for FDA acceptance in the second quarter of 2025.
Furthermore, Aquestive is preparing for a potential US launch in the first quarter of 2026, contingent on approval. The pediatric trial data suggests that Anaphylm could achieve a similar label to existing no-needle epinephrine products, although further studies are planned for younger patients. The overall market for Type 1 allergy treatments is expected to expand, and no-needle options like Anaphylm are anticipated to drive significant growth, supporting the Buy rating.
In another report released on April 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.